# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-456-A1)

In the	Application of:	)	
	Vouchase Islan	)	
	Varghese John	)	
		) Examiner: not assi	igned
Serial	No. TBA	)	
Intern	ational Application No. PCT/US03/20383	)	
		)	
Filed:	December 23, 2004	) Art Unit: TBA	
	ational Filing Date: June 27, 2003	)	
For:	Methods for Treating Alzheimer's Disease Using	)	
	Hydroxyethylene Compounds Containing A	ĺ	
	Heterocyclic Amide Bond Isostere	ĺ	

## INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This prior art statement is filed under 37 C.F.R. §§1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular; no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102.

10/519793

TT12 Rec'd PORIPTO 23 DEC 2004

**Foreign Documents** 

1. WO 98/224302 A, published May 28, 1998.

2. WO 01/70672 A, published September 27, 2001.

3. WO 02/02505 A, published January 10, 2002.

4. WO 03/047576 A, published June 12, 2003.

**Other Documents** 

5. Thompson, et al., Journal of Medicinal and Pharmaceutical Chemistry, American

Chemical Society (1994) Vol. 37, no. 19, pages 3100-3107.

Also, enclosed is a copy of the European Search Report in which all of the above-listed

references were cited during the prosecution of a corresponding PCT application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited

(including any cited in applicant's specification which is not repeated on the attached Form PTO-

1449) be given thorough consideration and that it be cited of record in the prosecution history of the

present application by initialing on Form PTO-1449. Such initialing is requested even if the

Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or

otherwise does not consider it to be prior art for any reason, or even if the Examiner does not

believe that the guidelines for citation have been fully complied with. This is requested so that each

document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

McDONNELL BOEHNEN

**HULBERT & BERGHOFF** 

300 South Wacker Drive

(312) 913-0004

Chicago, Illinois 60606

Dated: December 23, 2004

By:

Reg. No. 32,784

T12 Rec'd POT/PTO 2 3 DEC 2004 0/519793Sheet 1 of 1

U.S. Department of Commerce	Atty. Docket No.	Serial No.
I DISCLOSURE BY APPLICANT	02-456-A1	ТВА
eets if necessary)		
	December 23, 2004	ТВА
	Patent and Trademark Office I DISCLOSURE BY APPLICANT	Patent and Trademark Office  1 DISCLOSURE BY APPLICANT  Lets if necessary)  Applicant:  Varghese John  Filing Date:

#### **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Trans	Translation	
						Yes	No	
1	WO 98/22430	05/28/1998	PCT					
2	WO 01/70672	09/27/2001	PCT					
3	WO 02/02505	01/10/2001	PCT					
4	WO 047576	06/12/2003	PCT					

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

5	Thompson, et al., Journal of Medicinal and Pharmaceutical Chemistry, American Chemical Society (1994) Vol. 37, no. 19, pages 3100-3107.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.